# Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

> **NCT02378805** · — · RECRUITING · sponsor: **University Hospital Goettingen** · enrollment: 800 (estimated)

## Conditions studied

- Alport Syndrome
- Hereditary Kidney Disease
- Pediatric Kidney Disease
- Thin Basement Membrane Disease
- Familial Benign Hematuria

## Interventions

- **DRUG:** ACE-inhibitor
- **DRUG:** Angiotensin-receptor blocker (ARB)
- **DRUG:** HMG-Coenzyme inhibitor (statin)
- **DRUG:** Spironolactone or Finerenone
- **DRUG:** Paricalcitol
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT02378805
- **Lead sponsor:** University Hospital Goettingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 1995-07
- **Primary completion:** 2036-03-01
- **Final completion:** 2036-03-01
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378805, "Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02378805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*